MOR — Morphosys AG Share News
0.000.00%
Last trade - 00:00- €2.53bn
- €2.16bn
- €238.28m
Brief: Morphosys AG Says With Implementation Of Cost Optimization Measures Planned For 2024, Co Expects A 2024 Cash Burn Of Approximately EUR 250 Million
MorphoSys thrives on positive Pelabresib trial results
Brief: Morphosys Says Pelabresib Improves All Four Hallmarks Of Myelofibrosis In Phase 3 Manifest-2 Study
Europe Research Roundup: 3i Group, Phoenix, Zealand Pharma
Morphosys slumps after Pela Phase III MANIFEST2 trial prelim results
Morphosys slumps after Pela Phase III MANIFEST2 trial prelim results
Brief: Morphosys’ Phase 3 Study Of Pelabresib In Myelofibrosis Demonstrates Statistically Significant Improvement
Brief: Morphosys' Says Phase 3 Study Of Pelabresib In Myelofibrosis Demonstrates Statistically Significant Improvement In Spleen Volume Reduction And Strong Positive Trend In Symptom Reduction
Brief: MorphoSys AG Files For Potential Mixed Shelf Size Not Disclosed
Morphosys up after better than expected Q3, 'optimistic' Pelabresib comments
Brief: MorphoSys Q3 Revenue EUR 63.8 Million
Brief: Morphosys Q3 Net Loss Down 3% To EUR 119.6 Mln
Brief: Morphosys Updates Monjuvi U.S. Financial Guidance For 2023
GS ups Morphosys to 'neutral' ahead of MANIFEST-2 trial readout
Brief: Morphosys Says Receives U.S. FDA Fast Track Designation For Tulmimetostat In Endometrial Cancer
Brief: MorphoSys Q2 Revenue EUR 53.2 Million Vs. IBES Estimate EUR 54.2 Million
MorphoSys rises after double upgrade from JPM
Brief: Morphosys Says Q1 Consolidated Loss At EUR 44.4 Mln Vs EUR 122.7 Mln Year Ago
MorphoSys to present results of blood cancer drug study earlier, shares rise